BIOMAT Database Logo BIOMAT Database Logo

Making anti-cytokine therapy more selective: Studies in mice. 2018

Marina S Drutskaya, and Grigory A Efimov, and Irina V Astrakhantseva, and Andrei A Kruglov, and Sergei A Nedospasov
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia.

Cytokines are involved in a wide range of functions shaping the normal immune response, yet inflammatory changes in the immune system due to dysregulated cytokine signaling may lead to the induction of autoimmunity. Cytokine inhibitors have revolutionized the treatment of many autoimmune diseases in recent years. Systemic cytokine ablation, however, is often associated with the development of adverse side effects and some patients simply do not respond to therapy. TNF, IL-1 and IL-6 are the best characterized proinflammatory cytokines considered as the main therapeutic targets for the treatment of several autoimmune and inflammatory diseases. But can anti-cytokine therapy become more selective and thus more efficient? This mini-review discusses several recently emerging paradigms and summarizes current experimental attempts to validate them in mouse studies.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001327 Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. Autoimmune Disease,Disease, Autoimmune,Diseases, Autoimmune
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015551 Autoimmunity Process whereby the immune system reacts against the body's own tissues. Autoimmunity may produce or be caused by AUTOIMMUNE DISEASES. Autoimmune Response,Autoimmune Responses,Autoimmunities
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine

Related Publications

Marina S Drutskaya, and Grigory A Efimov, and Irina V Astrakhantseva, and Andrei A Kruglov, and Sergei A Nedospasov
Cytokine and anti-cytokine therapy for asthma.
March 2006, Current allergy and asthma reports,
Marina S Drutskaya, and Grigory A Efimov, and Irina V Astrakhantseva, and Andrei A Kruglov, and Sergei A Nedospasov
Making HIS mice more human-like.
January 2020, Journal of leukocyte biology,
Marina S Drutskaya, and Grigory A Efimov, and Irina V Astrakhantseva, and Andrei A Kruglov, and Sergei A Nedospasov
Making HIV therapy more manageable.
March 1998, RN,
Marina S Drutskaya, and Grigory A Efimov, and Irina V Astrakhantseva, and Andrei A Kruglov, and Sergei A Nedospasov
Making glaucoma genetic studies more diverse.
January 2024, Cell,
Marina S Drutskaya, and Grigory A Efimov, and Irina V Astrakhantseva, and Andrei A Kruglov, and Sergei A Nedospasov
Anti-cytokine therapy in rheumatoid arthritis.
November 1995, Bailliere's clinical rheumatology,
Marina S Drutskaya, and Grigory A Efimov, and Irina V Astrakhantseva, and Andrei A Kruglov, and Sergei A Nedospasov
Cytokine/anti-cytokine therapy - novel treatments for asthma?
May 2011, British journal of pharmacology,
Marina S Drutskaya, and Grigory A Efimov, and Irina V Astrakhantseva, and Andrei A Kruglov, and Sergei A Nedospasov
[Cytokine and anti-cytokine therapy in chronic inflammatory bowel diseases].
June 2001, Deutsche medizinische Wochenschrift (1946),
Marina S Drutskaya, and Grigory A Efimov, and Irina V Astrakhantseva, and Andrei A Kruglov, and Sergei A Nedospasov
Anti-cytokine therapy in systemic lupus erythematosus.
January 2005, Lupus,
Marina S Drutskaya, and Grigory A Efimov, and Irina V Astrakhantseva, and Andrei A Kruglov, and Sergei A Nedospasov
Anti-cytokine therapy in chronic destructive arthritis.
January 2001, Arthritis research,
Marina S Drutskaya, and Grigory A Efimov, and Irina V Astrakhantseva, and Andrei A Kruglov, and Sergei A Nedospasov
Anti cytokine therapy in chronic inflammatory arthritis.
October 2016, Cytokine,
Copied contents to your clipboard!